Toll-like receptor signaling pathways in cardiovascular diseases: Challenges and opportunities

International Reviews of Immunology

Volumn 31, Issue 5, 2012, Pages 379-395

  Moghimpour Bijani, Faezeh ^a   Vallejo, Jesus G ^b   Rezaei, Nima ^a,c,d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Atherosclerosis; Ischemic reperfusion injury; Pattern recognition receptors; Therapeutic strategy; TLR signaling; Toll like receptors

Indexed keywords

CARDIOVASCULAR AGENT; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; REACTIVE OXYGEN METABOLITE; RECEPTOR BLOCKING AGENT; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 11; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL INFILTRATION; CYTOKINE PRODUCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HUMAN; INNATE IMMUNITY; ISCHEMIC PRECONDITIONING; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW;

ATHEROSCLEROSIS; CYTOKINES; GENE EXPRESSION REGULATION; HEART FAILURE; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; MYELOID DIFFERENTIATION FACTOR 88; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84867799461     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2012.706761     Document Type: Article

References (146)

1. Arumugam TV, Okun E, Tang SC, Thundyil J, Taylor SM, Woodruff TM. Toll-like receptors in ischemia-reperfusion injury. Shock. 2009;32:4-16.
2. Rezaei N. Therapeutic targeting of pattern-recognition receptors. Int Immunopharmacol. 2006;6:863-869.
3. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. TrendsMolMed. 2007;13:460-469.
4. Kawai T, Akira S. TLR signaling. Semin Immunol. 2007;19:24-32.
5. Hornung V, Barchet W, Schlee M, Hartmann G. RNA recognition via TLR7 and TLR8. Handb Exp Pharmacol. 2008;183:71-86.
6. Krieg AM, Vollmer J. Toll-like receptors 7, 8, and 9: Linking innate immunity to autoimmunity. Immunol Rev. 2007;220:251-269.
7. Hedayat M, Takeda K, Rezaei N. Prophylactic and therapeutic implications of toll-like receptor ligands. Med Res Rev. 2012;32:294-325.
8. Horner AA, Redecke V, Raz E. Toll-like receptor ligands: Hygiene, atopy and therapeutic implications. Curr Opin Allergy Clin Immunol. 2004;4:555-561.
9. Doughty LA, Carlton S, Galen B, Cooma-Ramberan I, Chung CS, Ayala A. Activation of common antiviral pathways can potentiate inflammatory responses to septic shock. Shock. 2006;26:187-194.
10. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42:145-151.
11. Blander JM. Phagocytosis and antigen presentation: A partnership initiated by Toll-like receptors. Ann Rheum Dis. 2008;67 (Suppl 3):iii44-iii49.
12. Chao W, Shen Y, Zhu X, et al. Lipopolysaccharide improves cardiomyocyte survival and function after serumdeprivation. J Biol Chem. 2005;280:21997-2005.
13. Hodgkinson CP, Ye S. Toll-like receptors, their ligands, and atherosclerosis. ScientificWorldJournal. 2011;11:437-453.
14. Chang EJ, Kim HJ, Ha J, et al. Hyaluronan inhibits osteoclast differentiation via Toll-like receptor 4. J Cell Sci. 2007;120:166-176.
15. Smiley ST, King JA,HancockWW.Fibrinogen stimulatesmacrophage chemokine secretion through toll-like receptor 4. J Immunol. 2001;167:2887-2894.
16. Okamura Y,WatariM, Jerud ES, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem. 2001;276:10229-10233.
17. Funderburg N, Lederman MM, Feng Z, et al. Human β-defensin-3 activates professional antigenpresenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci U S A. 2007;104:18631-18635.
18. Yu M, Wang H, Ding A, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 2006;26:174-179.
19. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol. 2002;168:5233-5239.
20. Cohen-Sfady M, Nussbaum G, Pevsner-Fischer M, et al. Heat shock protein 60 activates B cells via the TLR4-MyD88 pathway. J Immunol. 2005;175:3594-3602.
21. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol. 2004;76:514-519.
22. Asea A, RehliM,Kabingu E, et al.Novel signal transduction pathway utilized by extracellularHSP70: Role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem. 2002;277:15028-15034.
23. Chen K, Huang J, GongW, Iribarren P, Dunlop NM,Wang JM. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol. 2007;7:1271-1285.
24. Scheibner KA, Lutz MA, Boodoo S, Fenton MJ, Powell JD,Horton MR. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol. 2006;177:1272-1281.
25. Dybdahl B, Wahba A, Lien E, et al. Inflammatory response after open heart surgery: Release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation. 2002;105: 685-690.
26. LinWJ, YehWC. Implication of Toll-like receptor and tumor necrosis factor alpha signaling in septic shock. Shock. 2005;24:206-209.
27. Cole JE, Georgiou E,Monaco C.The expression and functions of toll-like receptors in atherosclerosis. Mediators Inflamm. 2010;2010:3939-3946.
28. HedayatM,Netea MG, RezaeiN. Targeting of Toll-like receptors: A decade of progress in combating infectious diseases. Lancet Infect Dis. 2011;11:702-712.
29. Chao W. Toll-like receptor signaling: A criticalmodulator of cell survival and ischemic injury in the heart. Am J Physiol Heart Circ Physiol. 2009;296:H1-H12.
30. Meyer T, Stockfleth E. Clinical investigations of Toll-like receptor agonists. Expert Opin Investig Drugs. 2008;17:1051-1065.
31. Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol. 2006;117:979-987; quiz 88.
32. Terrell AM, Crisostomo PR, Wairiuko GM, Wang M, Morrell ED, Meldrum DR. Jak/STAT/SOCS signaling circuits and associated cytokine-mediated inflammation and hypertrophy in the heart. Shock. 2006;26:226-234.
33. Fan H, Peck OM, Tempel GE, Halushka PV, Cook JA. Toll-like receptor 4 coupled GI protein signaling pathways regulate extracellular signal-regulated kinase phosphorylation and AP-1 activation independent of NFkappaB activation. Shock. 2004;22:57-62.
34. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: Sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol. 2008;8:594-606.
35. Heinz S, Haehnel V, Karaghiosoff M, et al. Species-specific regulation of Toll-like receptor 3 genes in men and mice. J Biol Chem. 2003;278:21502-509.
36. Lin E, Freedman JE, Beaulieu LM. Innate immunity and toll-like receptor antagonists: A potential role in the treatment of cardiovascular diseases. CardiovascTher. 2009;27:117-123.
37. Nian M, Lee P,KhaperN, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004;94:1543-1553.
38. Thurman JM. Triggers of inflammation after renal ischemia/reperfusion. Clin Immunol. 2007;123:7-13.
39. Zingarelli B, Hake PW, Mangeshkar P, et al. Diverse cardioprotective signaling mechanisms of peroxisome proliferator-activated receptor-gamma ligands, 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone, in reperfusion injury: Role of nuclear factor-kappaB, heat shock factor 1, and Akt. Shock. 2007;28:554-563.
40. Rivo J, Zeira E, Galun E, Einav S, Linden J, Matot I. Attenuation of reperfusion lung injury and apoptosis by A2A adenosine receptor activation is associated with modulation of Bcl-2 and Bax expression and activation of extracellular signal-regulated kinases. Shock. 2007;27: 266-273.
41. Shernan SK, Collard CD. Role of the complement system in ischaemic heart disease: Potential for pharmacological intervention. BioDrugs. 2001;15:595-607.
42. HwangMW,Matsumori A, Furukawa Y, et al.Neutralization of interleukin-1beta in the acute phase ofmyocardial infarction promotes the progression of left ventricular remodeling. JAmColl Cardiol. 2001;38:1546-1553.
43. Giugliano GR, Giugliano RP, Gibson CM, Kuntz RE. Meta-analysis of corticosteroid treatment in acutemyocardial infarction. Am J Cardiol. 2003;91:1055-1059.
44. BujakM, Dobaczewski M, Chatila K, et al. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. AmJ Pathol. 2008;173:57-67.
45. Levonen AL, Vahakangas E, Koponen JK, Yla-Herttuala S. Antioxidant gene therapy for cardiovascular disease: Current status and future perspectives. Circulation. 2008;117:2142-2150.
46. Hsu SF, Niu KC, Lin CL, Lin MT. Brain cooling causes attenuation of cerebral oxidative stress, systemic inflammation, activated coagulation, and tissue ischemia/injury during heatstroke. Shock. 2006;26:210-220.
47. Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: Its fundamental role in mediating cell death during ischaemia and reperfusion. JMol Cell Cardiol. 2003;35:339-341.
48. PrechM,Marszalek A, Schroder J, et al. Apoptosis as amechanism for the elimination of cardiomyocytes after acutemyocardial infarction. Am J Cardiol. 2010;105:1240-1245.
49. Wu Y, Yin X, Wijaya C, Huang MH, McConnell BK. Acute myocardial infarction in rats. J Vis Exp. 2011;48:e2464.
50. Vanlangenakker N, Vanden Berghe T, Krysko DV, Festjens N, Vandenabeele P. Molecular mechanisms and pathophysiology of necrotic cell death. CurrMolMed. 2008;8:207-220.
51. Lavrik IN. [Regulation of death receptor-induced apoptosis induced via CD95/FAS and other death receptors].Mol Biol (Mosk). 2011;45:173-179.
52. Arumugam TV, Chan SL, Jo DG, et al. Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke. Nat Med. 2006;12:621-623.
53. Frantz S, Kobzik L, Kim YD, et al. Toll4 (TLR4) expression in cardiacmyocytes in normal and failing myocardium. J Clin Invest. 1999;104:271-280.
54. Roy SK, Srivastava RK, Shankar S. Inhibition of PI3K/AKT andMAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal. 2010;5:10.
55. Fang Y, Hu J. Toll-like receptor and its roles in myocardial ischemic/reperfusion injury. Med Sci Monit. 2011;17:RA100-RA109.
56. Israel A. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb Perspect Biol. 2010;2:a000158.
57. Ha T, Hua F, Liu X, et al. Lipopolysaccharide-induced myocardial protection against ischaemia/ reperfusion injury is mediated through a PI3K/Akt-dependent mechanism. Cardiovasc Res. 2008;78:546-553.
58. Shimamoto A, Chong AJ, Yada M, et al. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation. 2006;114:I270-I274.
59. Shishido T, Nozaki N, Yamaguchi S, et al. Toll-like receptor-2 modulates ventricular remodeling aftermyocardial infarction. Circulation. 2003;108:2905-2910.
60. Favre J,Musette P,Douin-EchinardV, et al.Toll-like receptors 2-deficientmice are protected against postischemic coronary endothelial dysfunction. ArteriosclerThromb Vasc Biol. 2007;27:1064-1071.
61. Arslan F, Smeets MB, O'Neill LA, et al. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-Toll-like receptor-2 antibody. Circulation. 2010;121:80-90.
62. Mersmann J, Koch A, Tran N, et al. Toll-like receptor 2 signaling triggers fatal arrhythmias upon myocardial ischemia-reperfusion. Crit CareMed. 2010;38:1927-1932.
63. Frantz S, Kelly RA, Bourcier T. Role of TLR-2 in the activation of nuclear factor kappaB by oxidative stress in cardiacmyocytes. J Biol Chem. 2001;276:5197-5203.
64. Zhu X, Bagchi A, ZhaoH, et al. Toll-like receptor 2 activation by bacterial peptidoglycan-associated lipoprotein activates cardiomyocyte inflammation and contractile dysfunction. Crit Care Med. 2007;35:886-892.
65. Hua F, Ha T, Ma J, et al. Blocking the MyD88-dependent pathway protects the myocardium from ischemia/reperfusion injury in rat hearts. Biochem Biophys Res Commun. 2005;338:1118-1125.
66. Feng Y, Zhao H, Xu X, et al. Innate immune adaptor MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. Am J Physiol Heart Circ Physiol. 2008;295:H1311-H1318.
67. Chao W. Toll-like receptor signaling: A criticalmodulator of cell survival and ischemic injury in the heart. Am J Physiol Heart Circ Physiol. 2009;296:1-12.
68. Dong JW, Vallejo JG, Tzeng HP,Thomas JA, Mann DL. Innate immunity mediates myocardial preconditioning through Toll-like receptor 2 and TIRAP-dependent signaling pathways. Am J Physiol Heart Circ Physiol. 2010;298:H1079-H1087.
69. Oppenheim JJ, Yang D. Alarmins: Chemotactic activators of immune responses. Curr Opin Immunol. 2005;17:359-365.
70. Yao YW, Zhang GH, Zhang YY, et al. Lipopolysaccharide pretreatment protects against ischemia/ reperfusion injury via increase of HSP70 and inhibition of NF-kappaB. Cell Stress Chaperones. 2011;16:287-296.
71. Schneider-Poetsch T, Ju J, Eyler DE, et al. Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nat Chem Biol. 2010;6:209-217.
72. Zhu X, ZhaoH, Graveline AR, et al.MyD88 and NOS2 are essential for Toll-like receptor 4-mediated survival effect in cardiomyocytes. Am J Physiol Heart Circ Physiol. 2006;291:H1900-H1909.
73. Wang Y, Guo Y, Zhang SX, et al. Ischemic preconditioning upregulates inducible nitric oxide synthase in cardiacmyocyte. JMol Cell Cardiol. 2002;34:5-15.
74. Maejima Y, Adachi S, Morikawa K, Ito H, Isobe M. Nitric oxide inhibits myocardial apoptosis by preventing caspase-3 activity via S-nitrosylation. JMol Cell Cardiol. 2005;38:163-174.
75. Yan ZQ,HanssonGK. Innateimmunity,macrophage activation, and atherosclerosis.Immunol Rev. 2007;219:187-203.
76. Erridge C, Burdess A, Jackson AJ, et al. Vascular cell responsiveness to Toll-like receptor ligands in carotid atheroma. Eur J Clin Invest. 2008;38:713-720.
77. Ott SJ, ElMokhtari NE,Musfeldt M, et al.Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. Circulation. 2006;113:929-937.
78. Laman JD, Schoneveld AH, Moll FL, van Meurs M, Pasterkamp G. Significance of peptidoglycan, a proinflammatory bacterial antigen in atherosclerotic arteries and its association with vulnerable plaques. AmJ Cardiol. 2002;90:119-123.
79. Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol. 2004;22:361-403.
80. Ngeh J, Anand V, Gupta S. Chlamydia pneumoniae and atherosclerosis - What we know and what we don't. ClinMicrobiol Infect. 2002;8:2-13.
81. Chen S, Sorrentino R, Shimada K, et al. Chlamydia pneumoniae-induced foam cell formation requiresMyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation. J Immunol. 2008;181:7186-7193.
82. Cao F, Castrillo A, Tontonoz P, Re F, Byrne GI. Chlamydia pneumoniae-inducedmacrophage foam cell formation ismediated by Toll-like receptor 2. Infect Immun. 2007;75:753-759.
83. MichelsenKS,WongMH,Shah PK, et al. Lack of Toll-like receptor 4 ormyeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype inmice deficient in apolipoprotein E. Proc Natl Acad Sci U S A. 2004;101:10679-10684.
84. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: A possible pathway for plaque activation. Circulation. 2002;105: 1158-1161.
85. Chang ZL. Important aspects of Toll-like receptors, ligands and their signaling pathways. Inflamm Res. 2010;59:791-808.
86. Su X, Ao L, Shi Y, Johnson TR, Fullerton DA,Meng X. Oxidized lowdensity lipoprotein induces bone morphogenetic protein-2 in coronary artery endothelial cells via Toll-like receptors 2 and 4. J Biol Chem. 2011;286:12213-12220.
87. Shuang C,Wong MH, Schulte DJ, Arditi M,Michelsen KS. Differential expression of Toll-like receptor 2 (TLR2) and responses to TLR2 ligands between human andmurine vascular endothelial cells. J Endotoxin Res. 2007;13:281-296.
88. Curtiss LK, Tobias PS. Emerging role of Toll-like receptors in atherosclerosis. J Lipid Res. 2009;50 (Suppl):S340-S345.
89. Muzio M, Bosisio D, Polentarutti N, et al. Differential expression and regulation of Toll-like receptors (TLR) in human leukocytes: Selective expression of TLR3 in dendritic cells. J Immunol. 2000;164:5998-6004.
90. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to differentmicrobial antigens. J ExpMed. 2001;194:863-869.
91. Visintin A,Mazzoni A, Spitzer JH,WyllieDH,Dower SK, SegalDM. Regulation of Toll-like receptors in humanmonocytes and dendritic cells. J Immunol. 2001;166:249-255.
92. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 2002;168:4531-4537.
93. Geng HL, Lu HQ, Zhang LZ, et al. Increased expression of Toll like receptor 4 on peripheralblood mononuclear cells in patients with coronary arteriosclerosis disease. Clin Exp Immunol. 2006;143:269-273.
94. Kuwahata S, Fujita S, Orihara K, et al. High expression level of Toll-like receptor 2 on monocytes is an important risk factor for arteriosclerotic disease. Atherosclerosis. 2010;209:248-254.
95. Ashida K, Miyazaki K, Takayama E, et al. Characterization of the expression of TLR2 (Toll-like receptor 2) and TLR4 on circulating monocytes in coronary artery disease. J Atheroscler Thromb. 2005;12:53-60.
96. Versteeg D, Hoefer IE, Schoneveld AH, et al.Monocyte Toll-like receptor 2 and 4 responses and expression following percutaneous coronary intervention: Association with lesion stenosis and fractional flow reserve. Heart. 2008;94:770-776.
97. Holvoet P,Davey PC,De KeyzerD, et al. Oxidized low-density lipoprotein correlates positively with Toll-like receptor 2 and interferon regulatory factor-1 and inversely with superoxide dismutase-1 expression: Studies in hypercholesterolemic swine and THP-1 cells. ArteriosclerThromb Vasc Biol. 2006;26:1558-1565.
98. BastaG, Schmidt AM,De Caterina R. Advanced glycation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004;63:582-592.
99. Libby P. Inflammation and cardiovascular diseasemechanisms.AmJ ClinNutr. 2006;83:456S-460S.
100. Hodgkinson CP, Laxton RC, Patel K, Ye S. Advanced glycation end-product of low density lipoprotein activates the Toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28:2275-2281.
101. Misciagna G, Logroscino G, DeMichele G, et al. Glycated apolipoprotein B andmyocardial infarction. NutrMetab Cardiovasc Dis. 2007;17:6-12.
102. Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010;11:155-161.
103. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol. 2003;14:421-30.
104. Binder CJ, Shaw PX, Chang MK, et al.The role of natural antibodies in atherogenesis. J Lipid Res. 2005;46:1353-1363.
105. Berliner JA, Watson AD. A role for oxidized phospholipids in atherosclerosis. N Engl J Med. 2005;353:9-11.
106. Berliner JA, Watson AD. A role for oxidized phospholipids in atherosclerosis. N Engl J Med. 2005;353:9-11.
107. Berliner JA, Leitinger N, Tsimikas S. The role of oxidized phospholipids in atherosclerosis. J Lipid Res. 2009;50 (Suppl):S207-S212.
108. Harkewicz R, Hartvigsen K, Almazan F, Dennis EA, Witztum JL, Miller YI. Cholesteryl ester hydroperoxides are biologically active components of minimally oxidized low density lipoprotein. J Biol Chem. 2008;283:10241-10251.
109. Miller YI, Viriyakosol S,Worrall DS, Boullier A, Butler S, Witztum JL. Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. ArteriosclerThromb Vasc Biol. 2005;25:1213-1219.
110. Bae YS, Lee JH, Choi SH, et al.Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: Toll-like receptor 4- And spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ Res. 2009;104:210-218, 21p following 8.
111. Choi SH, Harkewicz R, Lee JH, et al. Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circ Res. 2009;104:1355-1363.
112. Miller YI, Worrall DS, Funk CD, Feramisco JR, Witztum JL. Actin polymerization in macrophages in response to oxidized LDL and apoptotic cells: Role of 12/15-lipoxygenase and phosphoinositide 3-kinase.Mol Biol Cell. 2003;14:4196-4206.
113. Kalinina N, Agrotis A, Antropova Y, et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: Role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol. 2004;24:2320-2325.
114. Hodgkinson CP, Patel K, Ye S. Functional Toll-like receptor 4 mutations modulate the response to fibrinogen. Thromb Haemost. 2008;100:301-307.
115. Lee JY, Ye J, Gao Z, et al. Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem. 2003;278:37041-37051.
116. Weatherill AR, Lee JY, Zhao L, Lemay DG, Youn HS, Hwang DH. Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions mediated through TLR4. J Immunol. 2005;174:5390-5397.
117. Nowak JZ. [Anti-inflammatory pro-resolving derivatives of omega-3 and omega-6 polyunsaturated fatty acids]. Postepy HigMed Dosw (Online). 2010;64:115-132.
118. Midwood K, Sacre S, Piccinini AM, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med. 2009;15: 774-780.
119. Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: Host-associated molecular patterns for initiation andmodulation of inflammation. FASEB J. 2006;20:9-22.
120. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest. 2005;115:3149-3156.
121. Xu XH, Shah PK, Faure E, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001;104:3103-3108.
122. Mullick AE, Soldau K, Kiosses WB, Bell TA 3rd, Tobias PS, Curtiss LK. Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. J ExpMed. 2008;205:373-383.
123. Monaco C, Gregan SM, Navin TJ, Foxwell BM, Davies AH, Feldmann M. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation. 2009;120:2462-2469.
124. Liu X, Ukai T, Yumoto H, et al. Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis. 2008;196:146-154.
125. Kawakami A, Osaka M, Aikawa M, et al. Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circ Res. 2008;103:1402-1409.
126. Hoebe K, Georgel P, Rutschmann S, et al. CD36 is a sensor of diacylglycerides. Nature. 2005;433:523-527.
127. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol. 2007;7:179-190.
128. KimS, Takahashi H, LinWW,et al.Carcinoma-produced factors activatemyeloid cells through TLR2 to stimulatemetastasis. Nature. 2009;457:102-106.
129. Caron G, Duluc D, Fremaux I, et al. Direct stimulation of human T cells via TLR5 and TLR7/8: Flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J Immunol. 2005;175:1551-1557.
130. Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A. 2004;101:3029-3034.
131. Wesch D, Beetz S, Oberg HH,Marget M, Krengel K, Kabelitz D. Direct costimulatory effect of TLR3 ligand poly(I:C) on human gamma delta T lymphocytes. J Immunol. 2006;176:1348-1354.
132. Lee JG, Lim EJ, Park DW, Lee SH, Kim JR, Baek SH. A combination of Lox-1 and Nox1 regulates TLR9-mediated foam cell formation. Cell Signal. 2008;20:2266-2275.
133. Doyle SE, O'Connell RM, Miranda GA, et al. Toll-like receptors induce a phagocytic gene program through p38. J ExpMed. 2004;199:81-90.
134. Castrillo A, Joseph SB, Vaidya SA, et al. Crosstalk between LXR and Toll-like receptor signalingmediates bacterial and viral antagonism of cholesterol metabolism.Mol Cell. 2003;12:805-816.
135. Joseph SB, Castrillo A, Laffitte BA,Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipidmetabolism by liver X receptors. Nat Med. 2003;9:213-219.
136. Wagner M, Poeck H, Jahrsdoerfer B, et al. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol. 2004;172:954-963.
137. Agrawal S, Agrawal A, Doughty B, et al. Cutting edge: Different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signalregulated kinase-mitogen- activated protein kinase and c-Fos. J Immunol. 2003;171:4984-4989.
138. Manicassamy S, Ravindran R, Deng J, et al. Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nat Med. 2009;15:401-409.
139. Mallat Z, Gojova A, Brun V, et al. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockoutmice. Circulation. 2003;108:1232-1237.
140. GulenMF, Kang Z, Bulek K, et al.Thereceptor SIGIRR suppressesTh17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity. 2010;32:54-66.
141. Yu CF, PengWM, Oldenburg J, et al.Human plasmacytoid dendritic cells supportTh17 cell effector function in response to TLR7 ligation. J Immunol. 2010;184:1159-1167.
142. Chou MY, Fogelstrand L, Hartvigsen K, et al. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest. 2009;119:1335-1349.
143. Grimm M, Kim M, Rosenwald A, et al. Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression. Eur J Cancer. 2010;46:2849-2857.
144. Liu H, Komai-Koma M, Xu D, Liew FY. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci U S A. 2006;103:7048-7053.
145. Hasan U, Chaffois C, Gaillard C, et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol. 2005;174:2942-2950.
146. Cai Z, Shi Z, Sanchez A, et al. Transcriptional regulation of Tlr11 gene expression in epithelial cells. J Biol Chem. 2009;284:33088-33096.